Engineered nanostructural materials for application in cancer biology and medicine

Journal of Applied Toxicology

Volumn 32, Issue 1, 2012, Pages 10-19

  Mahmood, Meena ^a   Casciano, Dan ^a   Xu, Yang ^a   Biris, Alexandru S ^a  

^a UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

Author keywords

Cancer detection and therapy; Drug delivery; Gene therapy; Nanomedicine; Nanotoxicology

Indexed keywords

ANTINEOPLASTIC AGENT; MAGNETIC NANOPARTICLE; NANOMATERIAL;

ARTICLE; BIOCOMPATIBILITY; CANCER DIAGNOSIS; CANCER THERAPY; CYTOPLASM; DRUG DELIVERY SYSTEM; GENE THERAPY; HUMAN; HYPERTHERMIC THERAPY; MOLECULARLY TARGETED THERAPY; NANOENGINEERING; NANOTECHNOLOGY; NEOPLASM; PARTICLE SIZE; PRIORITY JOURNAL;

ANIMALS; DRUG DELIVERY SYSTEMS; EARLY DIAGNOSIS; GENE THERAPY; HUMANS; NANOSTRUCTURES; NANOTECHNOLOGY; NEOPLASMS;

EID: 83555165984     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1718     Document Type: Article

References (99)

1. Alivisatos AP. 2001. Less is more in medicine. Sci. Am. 285: 66-73.
2. Alonso A, Goni FM, Buckley JT. 2000. Lipids favoring inverted phase enhance the ability of aerolysin to permeabilize liposome bilayers. Biochemistry 39: 14019-14024.
3. Arimondo P, Boukarim C, Bailly C, Dauzonne D, Monneret C. 2000. Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 15: 413-421.
4. Bako J, Szepesi M, Marton I, Borbely J, Hegedus C. 2007. Synthesis of nanoparticles for dental drug delivery systems. Fogorv. Sz. 100: 109-113.
5. Ballestrero A, Rubagotti A, Stura P, Ferrando F, Amoroso D, Rinaldini M, Sismondi P, Genta F, Mesiti M, Brema F, Patrone F, Boccardo F, GROCTA (Italian Breast Cancer Adjuvant Study). 2001. Adjuvant chemotherapy with high-dose cyclophosphamide, etoposide and cisplatin intensification without progenitor cell support in breast cancer patients with ten or more involved nodes: 5-year results of a pilot trial. Oncology 60: 221-227.
6. Banerjee R. 2001. Liposomes: applications in medicine. J. Biomater. Appl. 16: 3-21.
7. Bhirde AA, Patel V, Gavard J, Zhang G, Sousa AA, Masedunskas A, Leapman RD, Weigert R, Gutkind JS, Rusling JF. 2009. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano 3: 307-316.
8. Bianco A, Kostarelos K, Partidos CD, Prato M. 2005. Biomedical applications of functionalised carbon nanotubes. Chem. Commun. (Cambridge) 5: 571-577.
9. Biris AS, Boldor D, Palmer J, Monroe WT, Mahmood M, Dervishi E, Xu Y, Li Z, Galanzha EI, Zharov VP. 2009. Nanophotothermolysis of multiple scattered cancer cells with carbon nanotubes guided by time-resolved infrared thermal imaging. J. Biomed. Opt. 14: 021007.
10. Borm P, Klaessig FC, Landry TD, Moudgil B, Pauluhn J, Thomas K, Trottier R, Wood S. 2006. Research strategies for safety evaluation of nanomaterials, part V: role of dissolution in biological fate and effects of nanoscale particles. Toxicol. Sci.: Offic. J. Soc. Toxicol. 90: 23-32.
11. Brannon-Peppas L, Blanchette JO. 2004. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56: 1649-1659.
12. Brigger I, Dubernet C, Couvreur P. 2002. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54: 631-651.
13. Brito L, Amiji M. 2007. Nanoparticulate carriers for the treatment of coronary restenosis. Int. J. Nanomedicine 2: 143-161.
14. Bromberg KD, Burgin AB, Osheroff N. 2003. A two-drug model for etoposide action against human topoisomerase IIalpha. J. Biol. Chem. 278: 7406-7412.
15. Busse D, Wurthwein G, Hinske C, Hempel G, Fromm MF, Eichelbaum M, Kroemer HK, Busch FW. 2002. Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration. Naunyn-Schmiedeberg's Arch. Pharmacol. 366: 218-225.
16. Byrne JD, Betancourt T, Brannon-Peppas L. 2008. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 60: 1615-1626.
17. Carpin LB, Bickford LR, Agollah G, Yu T, Schiff R, Li Y, Drezek RA. 2011. Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells. Breast Cancer Res. Treat. 125: 34.
18. Chen T. 2010. The role of microRNA in chemical carcinogenesis. J. Environ. Sci. Health C 28: 1-36.
19. Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM, Liu LF. 1984. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 259: 13560-13566.
20. Daniel MC, Astruc D. 2004. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem. Rev. 104: 293-346.
21. Dong W, Zhang T, Epstein J, Cooney L, Wang H, Li Y, Jiang Y, Cogbill A, Varadan V, Tian ZR. 2007. Multifunctional nanowire bioscafolds on titanium. Am. Chem. Soc. 19: 4454-4459.
22. Ferrari M. 2005. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5: 161-171.
23. Fonseca C, Simoes S, Gaspar R. 2002. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Controlled Release: Offic. J. Controlled Release Soc. 83: 273-286.
24. Fremgen AM, Bland KI, McGinnis LS Jr, Eyre HJ, McDonald CJ, Menck HR, Murphy GP. 1999. Clinical highlights from the National Cancer Data Base, 1999. CA Cancer J. Clin. 49: 145-158.
25. Galanzha EI, Shashkov EV, Kelly T, Kim JW, Yang L, Zharov VP. 2009. In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nat. Nanotechnol. 4: 855-860.
26. Hampel S, Kunze D, Haase D, Kramer K, Rauschenbach M, Ritschel M, Leonhardt A, Thomas J, Oswald S, Hoffmann V, Buchner B. 2008. Carbon nanotubes filled with a chemotherapeutic agent: a nanocarrier mediates inhibition of tumor cell growth. Nanomedicine (Lond.) 3: 175-182.
27. Hans ML, Lowman AM. 2002. Biodegradable nanoparticles for drug delivery and targeting. Curr. Opin. Solid State Mater. Sci. 6: 319-327.
28. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, Winer E, TLC D-99 Study Group. 2002. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94: 25-36.
29. Henwood JM, Brogden RN. 1990. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs 39: 438-490.
30. Herbert SM, Brames MJ, Einhorn LH. 2006. Emetic potential of daily oral etoposide. J. Clin. Oncol. 24: 18618.
31. Hirsch LR, Stafford RJ, Bankson JA, Sershen SR, Rivera B, Price RE, Hazle JD, Halas NJ, West JL. 2003. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc. Natl Acad. Sci. USA 100: 13549-13554.
32. Hortobagyi GN, Piccart-Gebhart MJ. 1996. Current management of advanced breast cancer. Semin. Oncol. 23: 1-5.
33. Huang X, El-Sayed IH, Qian W, El-Sayed MA. 2006a. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J. Am. Chem. Soc. 128: 2115-2120.
34. Huang X, Jain PK, El-Sayed IH, El-Sayed MA. 2006b. Determination of the minimum temperature required for selective photothermal destruction of cancer cells with the use of immunotargeted gold nanoparticles. Photochem. Photobiol. 82: 412-417.
35. Huang X, Qian W, El-Sayed IH, El-Sayed MA. 2007. The potential use of the enhanced nonlinear properties of gold nanospheres in photothermal cancer therapy. Lasers Surg. Med. 39: 747-753.
36. Husseini GA, Christensen DA, Rapoport NY, Pitt WG. 2002. Ultrasonic release of doxorubicin from Pluronic P105 micelles stabilized with an interpenetrating network of N, N-diethylacrylamide. J. Controlled Release: Offic. J. Controlled Release Soc. 83: 303-305.
37. Ikeda M, Noda K, Hiura M, Tamaya T, Ozaki M, Hatae M, Ozawa M, Yamabe T, Tanaka K, Izumi R, Okada H, Ogita Y, Hoshiai H. 1998. Late phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical cancer. ETP 21 Study Group - Cervical Cancer Group. Gan to Kagaku Ryoho Cancer Chemother. 25: 2249-2257.
38. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. 2008. Cancer statistics, 2008. CA Cancer J. Clin. 58: 71-96.
39. Kam NW, Dai H. 2005. Carbon nanotubes as intracellular protein transporters: generality and biological functionality. J. Am. Chem. Soc. 127: 6021-6026.
40. Kam NW, O'Connell M, Wisdom JA, Dai H. 2005. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc. Natl Acad. Sci. USA 102: 11600-11605.
41. Karmakar A, Bratton SM, Dervishi E, Ghosh A, Mahmood M, Xu Y, Saeed LM, Mustafa T, Casciano D, Pandya AR, Biris AS. 2011. Ethylenediamine functionalized-single walled nanotube (f-SWNT)-assisted in vitro delivery of oncogene suppressor p53 gene to breast cancer MCF-7 cells. Int. J. Nanmed. 6: 1045-1055.
42. Kim CS, Wilder-Smith P, Ahn YC, Liaw LH, Chen Z, Kwon YJ. 2009. Enhanced detection of early-stage oral cancer in vivo by optical coherence tomography using multimodal delivery of gold nanoparticles. J. Biomed. Opt. 14: 034008.
43. Kim JS, Amorino GP, Pyo H, Cao Q, Choy H. 2002. Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells. Radiother. Oncol.: J. Eur. Soc. Ther. Radiol. Oncol. 62: 61-67.
44. Ko YT, Kale A, Hartner WC, Papahadjopoulos-Sternberg B, Torchilin VP. 2009. Self-assembling micelle-like nanoparticles based on phospholipid-polyethyleneimine conjugates for systemic gene delivery. J. Controlled Release: Offic. J. Controlled Release Soc. 133: 132-138.
45. Kobayashi H, Kawashima Y. 1989. A case of recurrent uterine cervical cancer successfully treated with etoposide. Gan to Kagaku Ryoho. Cancer Chemother. 16: 3279-3282.
46. Koistinen P, Siitonen T, Mantymaa P, Savolainen ER. 2001. P53 and redox state in etoposide-induced acute myeloblastic leukemia cell death. Leukemia Res. 25: 1099-1105.
47. Lanza GM, Winter PM, Caruthers SD, Hughes MS, Cyrus T, Marsh JN, Neubauer AM, Partlow KC, Wickline SA. 2006. Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles. Nanomedicine (Lond.) 1: 321-329.
48. Liu B, Yang M, Li R, Ding Y, Qian X, Yu L, Jiang X. 2008a. The antitumor effect of novel docetaxel-loaded thermosensitive micelles. Eur. J. Pharm. Biopharm.: Offic. J. Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik eV 69: 527-534.
49. Liu Z, Chen K, Davis C, Sherlock S, Cao Q, Chen X, Dai H. 2008b. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 68: 6652-6660.
50. Loo C, Lowery A, Halas N, West J, Drezek R. 2005. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett. 5: 709-711.
51. Luther W. 2004. Industrial applications of nanomaterials - chances and risks. Technol. Anal. 54: 1-112.
52. Mahmood M, Karmakar A, Fejleh A, Mocan T, Iancu C, Mocan L, Iancu DT, Xu Y, Dervishi E, Li Z, Biris AR, Agarwal R, Ali N, Galanzha EI, Biris AS, Zharov VP. 2009. Synergistic enhancement of cancer therapy using a combination of carbon nanotubes and anti-tumor drug. Nanomedicine (Lond.) 4: 883-893.
53. Mahmood M, Casciano DA, Mocan T, Iancu C, Xu Y, Mocan L, Iancu DT, Dervishi E, Li Z, Abdalmuhsen M, Biris AR, Ali N, Howard P, Biris AS. 2010. Cytotoxicity and biological effects of functional nanomaterials delivered to various cell lines. J. Appl. Toxicol. 30: 74-83.
54. Martin ME, Rice KG. 2007. Peptide-guided gene delivery. AAPS J. 9: E18-29.
55. Maysinger D. 2007. Nanoparticles and cells: good companions and doomed partnerships. Org. Biomol. Chem. 5: 2335-2342.
56. McBain SC, Yiu HH, Dobson J. 2008. Magnetic nanoparticles for gene and drug delivery. Int. J. Nanomedicine 3: 169-180.
57. Miller J. 2003. Beyond biotechnology: FDA regulation of nanomedicine. Columbia Sci. Technol. Law Rev. 4: E5.
58. Mocellin S, Nitti D. 2008. TNF and cancer: the two sides of the coin. Front. Biosci.: J. Virtual Library 13: 2774-2783.
59. Mornet S, Vasseur S, Grasset F, Duguet E. 2004. Magnetic nanoparticle design for medical diagnosis and therapy. J. Mater. Chem. 14: 2161-2175.
60. Morshedi-Meibodi A, Uber PA, Mehra MR. 2003. Difficult cases in heart failure: chemotherapy-related cardiomyopathy - all that glitters is not gold. Congest. Heart Failure (Greenwich, Conn.) 9: 47-49.
61. Mykhaylyk O, Zelphati O, Rosenecker J, Plank C. 2008. siRNA delivery by magnetofection. Curr. Opin. Mol. Ther. 10: 493-505.
62. National Research Council. 2007. Toxicity Testing in the 21st Century - a Vision and a Strategy. The National Academies Press: Washington, DC.
63. Northfelt DW, Dezube BJ, Thommes JA, Levine R, Von Roenn JH, Dosik GM, Rios A, Krown SE, DuMond C, Mamelok RD. 1997. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J. Clin. Oncol.: Offic. J. Am. Soc. Clin. Oncol. 15: 653-659.
64. Nurgalieva Z, Liu CC, Du XL. 2010. Chemotherapy use and risk of bone marrow suppression in a large population-based cohort of older women with breast and ovarian cancer. Med. Oncol. (Northwood, Lond.).
65. Oberdorster G, Oberdorster E, Oberdorster J. 2005. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 113: 823-839.
66. Oyelere AK, Chen PC, Huang X, El-Sayed IH, El-Sayed MA. 2007. Peptide-conjugated gold nanorods for nuclear targeting. Bioconjug. Chem. 18: 1490-1497.
67. Panaretakis T, Pokrovskaja K, Shoshan MS, Grander D. 2002. Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. J. Biol. Chem. 277: 44317-44326.
68. Park JH, von Maltzahn G, Ong LL, Centrone A, Hatton TA, Ruoslahti E, Bhatia SN, Sailor MJ. 2010. Cooperative nanoparticles for tumor detection and photothermally triggered drug delivery. Adv. Mater. (Deerfield Beach, Fla) 22: 880-885.
69. Perkins CL, Fang G, Kim CN, Bhalla KN. 2000. The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res. 60: 1645-1653.
70. Prato M, Kostarelos K, Bianco A. 2008. Functionalized carbon nanotubes in drug design and discovery. Acc. Chem. Res. 41: 60-68.
71. Pulliam B, Sung JC, Edwards DA. 2007. Design of nanoparticle-based dry powder pulmonary vaccines. Expert Opin. Drug Deliv. 4: 651-663.
72. Ragusa A, Garcia I, Penades S. 2007. Nanoparticles as nonviral gene delivery vectors. IEEE Trans. Nanobiosci. 6: 319-330.
73. Rayman-Rasmussen JP, Riviere JE, Monteiro-Riviere NA. 2007. Variables infleuncing interactions of uncharged quantum dot nanoparticles with skin cells and identification of biochemical modulators. Nano Lett. 7: 1344-1348.
74. Rose PG, Blessing JA, Van Le L, Waggoner S. 1998. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol. Oncol. 70: 263-266.
75. Seo WS, Lee JH, Sun X, Suzuki Y, Mann D, Liu Z, Terashima M, Yang PC, McConnell MV, Nishimura DG, Dai H. 2006. FeCo/graphitic-shell nanocrystals as advanced magnetic-resonance-imaging and near-infrared agents. Nat. Mater. 5: 971-976.
76. Simeoni F, Morris MC, Heitz F, Divita G. 2003. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucl. Acids Res. 31: 2717-2724.
77. Simeoni F, Morris MC, Heitz F, Divita G. 2005. Peptide-based strategy for siRNA delivery into mammalian cells. Meth. Mol. Biol. (Clifton, NJ) 309: 251-260.
78. Sioud M, Forterre P, de Recondo AM. 1987. Effects of the antitumor drug VP16 (etoposide) on the archaebacterial Halobacterium GRB 1.7kb plasmid in vivo. Nucl. Acids Res. 15: 8217-8234.
79. Smart DJ, Halicka HD, Schmuck G, Traganos F, Darzynkiewicz Z, Williams GM. 2008. Assessment of DNA double-strand breaks and gammaH2AX induced by the topoisomerase II poisons etoposide and mitoxantrone. Mutat. Res. 641: 43-47.
80. Smith AM, Gao X, Nie S. 2004. Quantum dot nanocrystals for in vivo molecular and cellular imaging. Photochem. Photobiol. 80: 377-385.
81. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Rohl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP. 2004. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178.
82. Streicher RM, Schmidt M, Fiorito S. 2007. Nanosurfaces and nanostructures for artificial orthopedic implants. Nanomedicine (Lond.) 2: 861-874.
83. Teicher BA. 2008. Newer cytotoxic agents: attacking cancer broadly. Clin. Cancer Res.: Offic. J. Am. Assoc. Cancer Res. 14: 1610-1617.
84. Thomas E, Dumas P, Ajani JA. 1998. Oral etoposide for patients with advanced adenocarcinoma of the pancreas. Invest. New Drugs 16: 333-335.
85. Tong L, Zhao Y, Huff TB, Hansen MN, Wei A, Cheng JX. 2007. Gold nanorods mediate tumor cell death by compromising membrane integrity. Adv. Mater. (Deerfield Beach, Fla) 19: 3136-3141.
86. UK Royal Society and Royal Academy of Engineering. 2004. Nanoscience and Nanotechnologies: Opportunities and Uncertainties. Royal Society: London.
87. Van Horssen R, Ten Hagen TL, Eggermont AM. 2006. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11: 397-408.
88. Vilas GP, Swati VP, Aharon G. 2008. Semiconducting, magnetic or superconducting nanoparticles encapsulated in carbon shells by RAPET method. Carbon Sci. Technol. 1: 46-56.
89. Visaria RK, Griffin RJ, Williams BW, Ebbini ES, Paciotti GF, Song CW, Bischof JC. 2006. Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor-alpha delivery. Mol. Cancer Ther. 5: 1014-1020.
90. Von Maltzahn G, Park KH, Agrawal A, Bandaru NK, Das SK, Sailor MJ, Bhatia SN. 2009. Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res. 69: 3892-3900.
91. Wiradharma N, Tong YW, Yang YY. 2009. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect. Biomaterials 30: 3100-3109.
92. Xia T, Kovochich M, Brant J, Hotze M, Sempf J, Oberley T, Sioutas C, Yeh JI, Wiesner MR, Nel AE. 2006. Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett. 6: 1794-1807.
93. Xie FY, Woodle MC, Lu PY. 2006. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov. Today 11: 67-73.
94. Xu Y, Mahmood M, Li Z, Dervishi E, Trigwell S, Zharov VP, Ali N, Saini V, Biris AR, Lupu D, Boldor D, Biris AS. 2008. Cobalt nanoparticles coated with graphitic shells as localized RF absorbers for localized thermal tumor ablation. Nanotechnology 19: 435102-435110.
95. 4 cored magnetic-quantum dot fluorescent nanocomposites for RF nanohyperthermia of cancer cells. J. Phys. Chem. C 114: 5020-5026.
96. Xu Y, Mahmood M, Fejleh A, Li Z, Watanabe F, Trigwell S, Little RB, Kunets VP, Dervishi E, Biris AR, Salamo GJ, Biris AS. 2010b. Carbon-covered magnetic nanomaterials and their application for the thermolysis of cancer cells. Int. J. Nanomedicine 5: 167-176.
97. Zanello LP, Zhao B, Hu H, Haddon HC. 2006. Bone cell proliferation on carbon nanotubes. Nano Lett. 6: 562-567.
98. Zharov VP, Galitovsky V, Viegas M. 2003. Photothermal detection of local thermal effects during selective nanophotothermolysis. Appl. Phys. Lett. 83: 4897-4899.
99. Zharov VP, Galitovskaya EN, Jonson C, Kelly T. 2005. Synergistic enhancement of selective nanophotothermolysis with gold nanoclusters: potential for cancer therapy. Lasers Surg. Med. 37: 219-226.